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Stimulation of mar-oncogene transfected 401L-C3 cells by angiotensins leads to the production of inositol phosphates. 
This response shows dose dependence, and has an apparent rank order of potency angiotensin III > angiotensin II 9 an- 
giotensin I. Preincubation with 12-0-tetradecanoylphorbol 13-acetate, for 5 min, significantly diminishes both inositol 
phosphate and intracellular [Ca”] responses to angiotensins, without affecting those stimulated by the endogenous bra- 
dykinin receptor. Incubation of 4OlL-C3 cells with either phorbol ester or angiotensins leads to elevation of intracellular 
pH, implying that mus/angiotensin receptor stimulation itself leads to protein kinase C activation. These results suggest 
the operation of a negative feedback loop specific for the mas/angiotensin receptor signalling pathway, and which may 
be essential in defining the final biological output response to this receptor stimulation. 
Mur-oncogene/angiotensin receptor; Inositol phosphate; Ca 2+ intracellular; Tumour promoter 
1. INTRODUCTION 
The mus-oncogene is predicted to encode a pro- 
tein having 7 potential transmembrane cu-helices, 
and as such, to belong to a family of sensory recep- 
tors including the opsins, (Y- and ,&adrenergic, 
muscarinic acetylcholine and serotinergic receptors 
[l-3]. Amongst receptors thus far sequenced, the 
mas-oncogene itself shows greatest sequence iden- 
tity with the substance K receptor [4], leading to 
the prediction that its product would be a 
mitogenic peptide receptor capable of stimulating 
inositol phosphate and [Ca’+]i responses 131. Ex- 
pression of the mus-oncogene ither transiently, by 
injection of synthetic mas-mRNA into Xenopus 
oocytes, or stably, by transfection into 401L-C3 
neuronal cells, generated a novel sensitivity to 
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angiotensins, not present in either uninjected 
oocytes or the parental NG115-4OlL cell line [5]. 
In the 401L-C3 cells stimulation of the 
mas/angiotensin receptor leads to mobilisation of 
intracellular Ca’+, and also to the initiation of 
DNA synthesis. The parental NG115-4OlL cell line 
responds to stimulation of the endogenous 
bradykinin receptor by the production of inositol 
phosphates and a concomitant elevation of in- 
tracellular [Ca”] [6]. However, neither the paren- 
tal, nor the mus/angiotensin receptor-transfected 
401L-C3 cells exhibit mitogenic responses to 
bradykinin. This has led to the suggestion that the 
mas/angiotensin receptor may not actually operate 
via inositol lipid signalling, but may exert its ef- 
fects by coupling to a qualitatively different in- 
tracellular signalling pathway [7]. Here we report 
that stimulation of the mas/angiotensin receptor, 
in 401L-C3 cells, leads to the accumulation of in- 
ositol phosphates, to elevation of intracellular 
[Ca’+] and pH, and that these processes may be 
sensitive to regulation by protein kinase C. 
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2. MATERIALS AND METHODS 2.4. Measurement of intracellular pH in cell populations 
2.1. Cell culture 
4OlL-C3 cells were routinely cultured as monolayers in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 5% 
fetal-calf serum (FCS, v/v) and passaged by trypsinisation 
(O.OSSro, w/v) in divalent cation free phosphate buffered saline. 
For inositol lipid experiments cells were plated at a density of 
3 x I@ cells/cm’ on 6 well plates and grown for 3 days before 
the addition of radiolabel for the final 24 h: 1 &i of myo- 
[‘H]inositol(l2.8 Ci/mmol; NEN) in myo-inositol free DMEM 
(Gibco) supplemented with 5 PM myo-inositol and 5% dialysed 
FCS, per well. For population fluorescence measurements 1 x 
104 cells were plated on sterile 11 mm x 22 mm glass coverslips 
in 0.2 ml DMEM (5% FCS, v/v) supplemented 1h later with 
0.8 ml DMEM (SVo, FCS, v/v) and used 3 days later. 
Coverslips prepared as described above were incubated for 
30 min at 37°C with 5 ,uM BCECFIAM [9]. Cells were then 
washed with mHBS and maintained in this buffer at room 
temperature until ready for use (the omission of bicarbonate 
from the original Hanks balanced salts recipe allowing observa- 
tion of changes in pHi, without any contribution to intracellular 
buffering from the HCO$-/Cl*- exchange). Coverslips were 
loaded into a cuvette containing 1.5 ml of mHBS and position- 
ed as described above. Excitation and emission wavelengths of 
485 nm and 530 nm, respectively, were chosen so that a rise in 
intracellular pH gave a corresponding increase in fluorescence 
intensity. 
3. RESULTS AND DISCUSSION 
2.2. Assay for fH]inositol phosphate production 
The labelling medium was removed and each well was washed 
twice with modified Hank’s buffered saline (mHBS: 1 mM 
CaC12, 5.4 mM KCI, 0.5 mM MgCL, 0.2 mM MgS04, 137 mM 
NaCI, 44 mM glucose, 20 mM Hepes, pH 7.4) and prein- 
cubated in this medium with the addition of 10 mM LiCl, for 
15 min at 37”C, 12-0-tetradecanoylphorbol 13-acetate (TPA) 
being added for the final 5 min as appropriate. The preincuba- 
tion medium was then replaced with fresh prewarmed medium 
containing the appropriate drugs, and 10 mM LiCI. Incuba- 
tions were terminated by addition of an equivalent volume of 
ice-cold 10% (v/v) HC104; after 5 min on ice, the supernatant 
was removed (EDTA added to a final concentration of 10 mM) 
and neutralised by addition of an excess of (1.2: 1, v/v) tri-n- 
octylamine/l, 1,2-trichloro-trifluoroethane (Freon) (1: 1, v/v, 
see 181). Solble [‘Hlinositol metabolites were then separated by 
ion-exchange chromatography on 1 cm columns of Dowex 
AGlX8 resin (formate form, Biorad), with batchwise lution as 
follows; free inositol with 2 x 5 ml of distilled water; 
glycerophoshoinositol-containing fraction with 2 x 5 ml of 
60 mM sodium formate/ mM disodium tetraborate; mixed in- 
ositol mono-, bis-, tris-, and tetrakis-phosphates were eluted by 
addition of 1.2 M ammonium formate/O.l M formic acid. The 
activity in each fraction was determined by liquid scintillation 
spectrophotometry. Elution positions were verified by co- 
chromatography with known radiochemical standards. 
Stimulation of mas-oncogene-transfected 401L- 
C3 cells, prelabelled with [3H]inositol, with 
2.3. Measurement of intracelhdar [Cd+j in ceil populations 
Coverslips coated with cells, as described above, were in- 
cubated in DMEM containing 2rM fura-2/acetoxy methyl 
ester for 45 min at 37”C, washed, and put into mHBS at 37°C 
and allowed to cool to room temperature for maintenance prior 
to use. 
Before addition of agonists, coverslips were placed across the 
diagonal of a 0.5 cm path length quartz cuvette, containing 
1.5 ml of mHBS with either 1 mM CaC12. The cuvette was then 
placed with the coverslip at 60” to incident light, and such that 
light fell directly onto the cells without passing through the glass 
coverslip, in a Perkin-Elmer 3000 fluorescence spec- 
trophotometer with a cuvette holder thermostatically maintain- 
ed at 37°C. Excitation and emission wavelengths of 340 nm and 
500 nm, respectively, were chosen so that increasing [Ca’+]i 
gives an increase in fluorescence intensity. Calibration and 
calculation of [Ca’+]r was as previously described [9]. 
angiotensins I, II or III results in the accumulation 
of inositol phosphates (fig.la). As previously 
reported for Ca2+ responses in 401L-C3 cells, both 
AI11 and AI1 show greater potency than equivalent 
doses of AI (AI11 significantly different from AI, 
p < 0.05 as determined by Student’s t-test (two tail- 
ed)). Further, the stimulation of [3H]Ins P ac- 
cumulation by angiotensin III (AIII) is dose 
dependent (fig.lb) giving a maximal increase in 
Ins Pi-4 of around 150 f 5% of control (typical 
basal and stimulated values; 600 + 40 cpm and 970 
f 100 cpm, respectively). Preincubation of cells 
with 200 nM 12-0-tetradecanoylphorbol 13-acetate 
(TPA), for 5 min, has no significant effect on 
basal [3H]inositol phosphate levels, but totally 
abolishes the accumulation stimulated by 100 nM 
angiotensin III (fig.lc: AI11 alone different from 
AI11 after TPA; p < 0.05 by Student’s t-test). This 
effect is specific to the accumulation stimulated by 
the mas/angiotensin receptor, as preincubation 
with 200 nM TPA has no significant effect on the 
[3H]Ins P response stimulated by bradykinin in 
these cells (fig.la and c; maximal stimulated ac- 
cumulation around 280 f 25% of control, typical 
basal and stimulated values; 600 + 25 cpm and 
1600 f 300 cpm, respectively; bradykinin alone 
not significantly different from bradykinin after 
TPA; p > 0.05 by Student’s t-test (two tailed)). 
401L-C3 cells, prelabelled with the intracellular- 
ly trapped, fluorescent Ca2+ indicator fura-2, show 
a basal intracellular [Ca2’] of around 100 & 
60 nM, stimulation by angiotensin II leads to a rise 
in [Ca’+]i to a peak value of around 500 rt 140 nM 
after 15 s, returning to near basal levels some 60 s 
28 
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Fig. 1. lnositol phosphate production stimulated by 
angiotensins: (a) relative potency; (b) dose dependence; (c) 
inhibition by TPA. TPA preincubation, 5 min; all agonist 
incubations, 30 min. Data are presented as mean rt SE, from 3 
to 4 separate xperiments, each performed in triplicate. 
later. Pretreatment with TPA (200 nM, 5 min) 
does not alter basal [Ca’+]i but leads to a substan- 
tial diminution of the peak [Ca2+]i level attained 
15 s after stimulation with 100 nM angiotensin II 
(fig.2). 
The magnitude of the angiotensin-stimulated 
inositol phosphate responses een in 401L-C3 cells 
are similar to those described in primary cultures 
of both arterial smooth muscle [lo] and renal 
mesangial cells [ 1 l] endogenously expressing 
angiotensin receptors. Endogenous angiotensin 
responses also show sensitivity to inhibition by 
protein kinase C activators [ll, 121 and, in renal 
mesangial cells, it appears that it is the angiotensin 
receptor itself which is the target of protein kinase 
C [13]. Further, the presence of potential protein 
kinase C phosphorylation sites in the mas/angio- 
tensin receptors predicted protein product support 
its role as a point of regulation of receptor effector 
coupling. 
Stimulation of a phospholipase C coupled 
angiotensin receptor, leading to the concomitant 
production of inositol phosphates and diacylglyc- 
erol, may itself lead to activation of protein kinase 
C. One convenient marker of protein kinase C 
stimulation is provided by the rise in intracellular 
pH following activation of the Na+/H+ antiporter 
[9,14]. Thus in 401L-C3 cells loaded with the, in- 
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Fig.2. Preincubation with 200 nM TPA diminishes peak [Ca’+]i 
response to 1 pM angiotensin II but not that to successive 
stimulation with 1 pM bradykinin. Data are mean + SE from 
at least 5 separate determinations. 
tracellularly trapped, fluorescent pH indicator dye 
BCECF addition of 200 nM TPA leads to an in- 
crease in fluorescence corresponding to an increase 
in intracellular pH. A similar increase in BCECF 
fluorescence is recorded in response to 1 PM 
angiotensin III, implying that stimulation of the 
mas/angiotensin receptor may itself lead to activa- 
tion of protein kinase C and the Na+/H+ an- 
tiporter (fig.3). 
The activation of protein kinase C in response to 
angiotensin stimulation of the mas-oncogene may 
provide a negative feedback loop by which the ac- 
tivity of this receptor is regulated. Such feedback 
loops have been reported to limit responses to 
other mitogenic inositol phosphate and Ca2+ 
mobilising receptors, such as, the Vl vasopressin 
TtpA t-Y 
j,, 
Fig.3. TPA (200 nM), angiotensin III (1 PM) and bradykinin 
(1 PM) stimulate levation of intracellular pH as indicated by an 
increase in BCECF fluorescence. Traces are representative of at 
least 5 separate determinations. 
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and bombesin receptors in Swiss 3T3 fibroblasts 
[ 151. The rapid activation of such a feedback pro- 
cess could slow the initial production of inositol 
phosphates and diacylglycerol after mas/angioten- 
sin receptor stimulation, resulting in the slower 
kinetics observed for both Ca2+ [5] and pH 
responses when compared with those.stimulated by 
bradykinin. This process may also be responsible 
for the more limited production of inositol 
phosphates in response to angiotensins than 
bradykinin in the 401L-C3 cells. A similar dispari- 
ty in the ability of mitogenic and non-mitogenic 
receptors to stimulate inositol phosphate produc- 
tion has been reported in human fibroblasts 
responding to thrombin or bombesin [16], leading 
to the suggestion that the operation of such tightly 
regulated negative feedback loops is important in 
generating mitogenic responses. One possible ex- 
planation for this may be found in the recent 
observations that protein kinase C activation 
following an initial mitogenic stimulus may actual- 
ly inhibit cell cycle progression [17,18], thus it may 
be characteristic of mitogenic inositol phosphate 
mobilising receptors that their activity is damped 
once their initial cellular signalling event is com- 
pleted. 
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